Cognitive behavioural treatment of negative symptoms in patients with schizophrenic disorders

ISRCTN ISRCTN25455020
DOI https://doi.org/10.1186/ISRCTN25455020
Protocol serial number KL1179/3-1
Sponsor University Hospital Tuebingen (Germany)
Funder German Research Foundation (Deutsche Forschungsgemeinschaft) (Germany), grant KL1179/3-1
Submission date
16/09/2005
Registration date
21/11/2005
Last edited
06/09/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Stefan Klingberg
Scientific

Department of Psychiatry and Psychotherapy
Osianderstr. 24
Tuebingen
D-72076
Germany

Email stefan.klingberg@med.uni-tuebingen.de

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Scientific title
Study acronymTONES
Study objectivesCognitive Behavioural Treatment (CBT) is more efficacious in reducing negative symptoms (PANSS modified negative symptom factor) in schizophrenic disorders than Cognitive Remediation (CR)
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedSchizophrenia
InterventionCognitive Behavioural Treatment versus Cognitive Remediation
Intervention typeOther
Primary outcome measure(s)

PANSS Modified Negative Factor (N1, N2, N3, N4, N6, G7, G16)

Key secondary outcome measure(s)

1. Illness related events
2. Scale for the Assessment of Negative Symptoms (SANS)
3. Calgary Depression Scale for Schizophrenia (CDSS)
4. Clinical Global Impression (CGI)
5. Lancashire Quality of Life Profile (LQLP)
6. Social Status
7. Medication Compliance
8. Symptom Checklist 90 Revised (SCL-90-R)
9. Frontal Eye Fields (FEF)
10. Frankfurt Self-concept Scale (FSKN)
11. Neuropsychological assessment

Completion date31/12/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration198
Key inclusion criteria1. Schizophrenia (Diagnostic and Statistical Manual of Mental Disorders - fourth edition [DSM-IV] 295.1, 295.2, 295.3, 295.4, 295.6, 295.9)
2. PANSS Modified Negative Syndrome Score ≥10
3. Fluency of German language
Key exclusion criteria1. Severe positive symptoms (any item of the standard PANSS positive scale [P1, P2, P3, P4, P5, P6, P7] ≥6)
2. Severe depression as indicated by PANSS G6 ≥6
3. Extrapyramidal symptoms
4. Age below 18 or over 55
5. Organic disorder interfering with the central nervous system
6. Verbal IQ <80
7. Diagnosis of substance abuse or substance dependence according to DSM-IV/Structured Clinical Interview for Depression (SCID-I) as primary clinical problem
8. Travel time to the study centre of more than 1 hour
Date of first enrolment01/01/2006
Date of final enrolment31/12/2007

Locations

Countries of recruitment

  • Germany

Study participating centre

Department of Psychiatry and Psychotherapy
Tuebingen
D-72076
Germany

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2011 Yes No